EUVIMEDEUVIMED entdecken
Open Access

Mutational scanning of CRX classifies clinical variants and reveals biochemical properties of the transcriptional effector domain

James L Shepherdson iD, David M Granas, Jie Li, Zara Shariff iD, Stephen P Plassmeyer iD, Alex S Holehouse iD, Michael A White iD, Barak A Cohen iD

Genome Research · 2024-10 · 34 (10) · 1540-1552

DOI: 10.1101/gr.279415.124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genome Research, online erschienen am 25.09.2024. Verfasst von James L Shepherdson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA. Hauptthemen laut MEDLINE: Homeodomain Proteins, Trans-Activators. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transcription factor (TF) cone-rod homeobox (CRX) is essential for the differentiation and maintenance of photoreceptor cell identity. Several human CRX variants cause degenerative retinopathies, but most are variants of uncertain significance. We performed a deep mutational scan (DMS) of nearly all possible single amino acid substitutions in CRX using a cell-based transcriptional reporter assay, curating a high-confidence list of nearly 2000 variants with altered transcriptional activity. In the structured homeodomain, activity scores closely aligned to a predicted structure and demonstrated position-specific constraints on amino acid substitution. In contrast, the intrinsically disordered transcriptional effector domain displayed a qualitatively different pattern of substitution effects, following compositional constraints without specific residue position requirements in the peptide chain. These compositional constraints were consistent with the acidic exposure model of transcriptional activation. We evaluated the performance of the DMS assay as a clinical variant classification tool using gold-standard classified human variants from ClinVar, identifying pathogenic variants with high specificity and moderate sensitivity. That this performance could be achieved using a synthetic reporter assay in a foreign cell type, even for a highly cell type-specific TF like CRX, suggests that this approach shows promise for DMS of other TFs that function in cell types that are not easily accessible. Together, the results of the CRX DMS identify molecular features of the CRX effector domain and demonstrate utility for integration into the clinical variant classification pipeline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homeodomain ProteinsTrans-ActivatorsHumansProtein DomainsAmino Acid SubstitutionDNA Mutational AnalysisMutationGenetic Variation

Substanzen

Homeodomain Proteinscone rod homeobox proteinTrans-Activators

Autor:innen und Institutionen

  • Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA.
  • Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA.
  • Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA.
  • Center for Biomolecular Condensates, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA.
  • Department of Genetics, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, USA; cohen@wustl.edu.

ORCID-Profile: James L Shepherdson, Zara Shariff, Stephen P Plassmeyer, Alex S Holehouse, Michael A White, Barak A Cohen

Förderung

  • NEI NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NHGRI NIH HHS
  • Alvin J. Siteman Cancer Center Flow Cytometry Core
  • National Institutes of Health
  • National Institute of General Medical Sciences
  • National Human Genome Research Institute

Zitieren

APA

Shepherdson, J. L., Granas, D. M., Li, J., Shariff, Z., Plassmeyer, S. P., Holehouse, A. S., White, M. A., & Cohen, B. A. (2024). Mutational scanning of CRX classifies clinical variants and reveals biochemical properties of the transcriptional effector domain. Genome Research, 34(10), 1540-1552. https://doi.org/10.1101/gr.279415.124

Vancouver

Shepherdson JL, Granas DM, Li J, Shariff Z, Plassmeyer SP, Holehouse AS, et al. Mutational scanning of CRX classifies clinical variants and reveals biochemical properties of the transcriptional effector domain. Genome Research. 2024;34(10):1540-1552. doi:10.1101/gr.279415.124

BibTeX
@article{Shepherdson2024,
  author = {Shepherdson, James L and Granas, David M and Li, Jie and Shariff, Zara and Plassmeyer, Stephen P and Holehouse, Alex S and White, Michael A and Cohen, Barak A},
  title = {Mutational scanning of CRX classifies clinical variants and reveals biochemical properties of the transcriptional effector domain},
  journal = {Genome Research},
  year = {2024},
  volume = {34},
  number = {10},
  pages = {1540--1552},
  doi = {10.1101/gr.279415.124}
}
Kostenlos starten →